PDCD1 and breast carcinoma: In the context of PD-1 inhibition, lack of changes in MDA-MB-231 breast cancer cell proliferation would appear to be in accordance with previous data indicating no effects on survival and metastasis of tumors treated only with anti-PD-1 antibodies [20].